Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure

Mark C. Genovese, Andrea Rubbert-Roth, Josef S. Smolen, Joel Kremer, Majed Khraishi, Juan Gómez-Reino, Anthony Sebba, Robert Pilson, Sarah Williams and Ronald Van Vollenhoven
The Journal of Rheumatology June 2013, 40 (6) 768-780; DOI: https://doi.org/10.3899/jrheum.120687
Mark C. Genovese
From the Division of Rheumatology, Stanford University Medical Center, Palo Alto, California, USA; Department of Internal Medicine, University of Cologne, Cologne, Germany; Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Center for Rheumatology, Albany Medical College, State University of New York, Albany, New York, USA; Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada; Rheumatology Unit Hospital, Clinical Universitario, Santiago, Spain; Department of Rheumatology, University of South Florida, Palm Harbor, Florida, USA; Hoffmann-La Roche Inc., Nutley, New Jersey, USA; PDBB-Biostatistics, Roche Products Limited, Welwyn Garden City, UK; and Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Genovese@stanford.edu
Andrea Rubbert-Roth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josef S. Smolen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Kremer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Majed Khraishi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan Gómez-Reino
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Sebba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Pilson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Williams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald Van Vollenhoven
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

REFERENCES

  1. 1.↵
    1. Lee DM,
    2. Weinblatt ME
    . Rheumatoid arthritis. Lancet 2001;358:903–11.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Scott DL
    . Radiological progression in established rheumatoid arthritis. J Rheumatol Suppl. 2004 Mar;69:55–65.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Welsing PM,
    2. van Gestel AM,
    3. Swinkels HL,
    4. Kiemeney LA,
    5. van Riel PL
    . The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009–17.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Salaffi F,
    2. Carotti M,
    3. Gasparini S,
    4. Intorcia M,
    5. Grassi W
    . The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: A comparison with a selected sample of healthy people. Health Qual Life Outcomes 2009;7:25.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Lundkvist J,
    2. Kastang F,
    3. Kobelt G
    . The burden of rheumatoid arthritis and access to treatment: Health burden and costs. Eur J Health Econ 2008;8:S49–60.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Mihara M,
    2. Kasutani K,
    3. Okazaki M,
    4. Nakamura A,
    5. Kawai S,
    6. Sugimoto M,
    7. et al.
    Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005;5:1731–40.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Smolen JS,
    2. Beaulieu A,
    3. Rubbert-Roth A,
    4. Ramos-Remus C,
    5. Rovensky J,
    6. Alecock E,
    7. et al.
    Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987–97.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Genovese MC,
    2. McKay JD,
    3. Nasonov EL,
    4. Mysler EF,
    5. da Silva NA,
    6. Alecock E,
    7. et al.
    Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968–80.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Emery P,
    2. Keystone E,
    3. Tony HP,
    4. Cantagrel A,
    5. van Vollenhoven R,
    6. Sanchez A,
    7. et al.
    IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516–23.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Jones G,
    2. Sebba A,
    3. Gu J,
    4. Lowenstein MB,
    5. Calvo A,
    6. Gomez-Reino JJ,
    7. et al.
    Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69:88–96.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Kremer JM,
    2. Blanco R,
    3. Brzosko S,
    4. Burgos-Vargas R,
    5. Halland AM,
    6. Vernon E,
    7. et al.
    Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609–21.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Nishimoto N,
    2. Miyasaka N,
    3. Yamamoto K,
    4. Kawai S,
    5. Takeuchi T,
    6. Azuma J
    . Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2008;68:1580–4.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Schiff MH,
    2. Kremer JM,
    3. Jahreis A,
    4. Vernon E,
    5. Isaacs JD,
    6. van Vollenhoven RF
    . Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13(R141):1–13.
    OpenUrl
  14. 14.↵
    1. Genentech Inc
    . Actemra (tocilizumab) prescribing information. Genentech Inc. South San Francisco, CA: Genentech Inc.; 2010. [Internet. Accessed December 13, 2012.] Available from: www.gene.com/gene/products/information/actemra/pdf/pi.pdf
  15. 15.↵
    1. Felson DT,
    2. Smolen JS,
    3. Wells G,
    4. Zhang B,
    5. van Tuyl LH,
    6. Funovits J,
    7. et al.
    American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404–13.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Curtis JR,
    2. Xie F,
    3. Chen L,
    4. Spettell C,
    5. McMahan RM,
    6. Fernandes J,
    7. et al.
    The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum 2011;63:346–51.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Solomon DH,
    2. Karlson EW,
    3. Rimm EB,
    4. Cannuscio CC,
    5. Mandl LA,
    6. Manson JE,
    7. et al.
    Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303–7.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Watson DJ,
    2. Rhodes T,
    3. Guess HA
    . All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003;30:1196–202.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Solomon DH,
    2. Goodson NJ,
    3. Katz JN,
    4. Weinblatt ME,
    5. Avorn J,
    6. Setoguchi S,
    7. et al.
    Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65:1608–12.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Fransen J,
    2. van Riel PL
    . DAS remission cut points. Clin Exp Rheumatol 2006;24:S29–32.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 40, Issue 6
1 Jun 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
Mark C. Genovese, Andrea Rubbert-Roth, Josef S. Smolen, Joel Kremer, Majed Khraishi, Juan Gómez-Reino, Anthony Sebba, Robert Pilson, Sarah Williams, Ronald Van Vollenhoven
The Journal of Rheumatology Jun 2013, 40 (6) 768-780; DOI: 10.3899/jrheum.120687

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
Mark C. Genovese, Andrea Rubbert-Roth, Josef S. Smolen, Joel Kremer, Majed Khraishi, Juan Gómez-Reino, Anthony Sebba, Robert Pilson, Sarah Williams, Ronald Van Vollenhoven
The Journal of Rheumatology Jun 2013, 40 (6) 768-780; DOI: 10.3899/jrheum.120687
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

TOCILIZUMAB
TREATMENT EFFICACY
SAFETY
RHEUMATOID ARTHRITIS

Related Articles

Cited By...

More in this TOC Section

  • Dactylitis Is Associated With More Severe Axial Joint Damage and Higher Disease Activity in Axial Psoriatic Arthritis
  • Health Outcomes of 215 Mothers of Children With Autoimmune Congenital Heart Block: Analysis of the French Neonatal Lupus Syndrome Registry
  • Antimelanoma Differentiation-Associated Gene 5 Antibody–Positive Interstitial Lung Disease After Vaccination With COVID-19 mRNA Vaccines
Show more Articles

Similar Articles

Keywords

  • tocilizumab
  • treatment efficacy
  • safety
  • rheumatoid arthritis

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire